SESSION 6 - Side Effects
Participants Clinical Case Discussion: Treatment of Metastatic RCC Patient with Hepatotoxicity
Date
03 Sep 2020Session
SESSION 6 - Side EffectsPresenters
B. Oztosun, TRResources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Tyrosine Kinase Inhibitors and mTOR Inhibitors in RCC
Presenter: T. Rajasekaran, SG
Session: SESSION 6 - Side Effects
Resources:
Slides
Webcast
Participants Clinical Case Discussion: 4 Years Survival of mRCC Without Immunotherapy
Presenter: V. Talreja, IN
Session: SESSION 6 - Side Effects
Resources:
Slides
Webcast
Immunotherapy
Presenter: L. Albiges, FR
Session: SESSION 6 - Side Effects
Resources:
Webcast
Chemotherapy
Presenter: R. Kanesvaran, SG
Session: SESSION 6 - Side Effects
Resources:
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.